ABO2102 for KRAS-mutated advanced solid tumors
Official title: A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of ABO2102 in Participants With KRAS Mutant Solid Tumors
Run by Suzhou Abogen Biosciences Co., Ltd. · NCT07455617 · Data updated 2026-11-12
This study tests whether ABO2102, alone or combined with the immunotherapy drug sintilimab, is safe and shows early anti-tumor activity in adults with advanced solid tumors that have KRAS mutations.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 101 (estimated) |
| Sponsor | Suzhou Abogen Biosciences Co., Ltd. Industry-sponsored |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | March 24, 2026 |
| Main results expected | June 2029 |
| Study ends | February 2030 |
| Registry record updated | April 6, 2026 |
| Trial ID | NCT07455617 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with genetically confirmed KRAS-mutated locally advanced or metastatic solid tumors, at least one measurable lesion, adequate organ function, and willingness to use effective contraception are the intended participants.
✕Probably not a fit
Patients without KRAS mutations, those with recent other active cancers, or those with severe hematologic, hepatic, renal or coagulation dysfunction are unlikely to benefit or be eligible for this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, open-label Phase 1 trial that gives ABO2102 as monotherapy and in combination with sintilimab to adults with histologically confirmed advanced or metastatic solid tumors harboring KRAS mutations. The study requires at least one measurable lesion per RECIST v1.1 and collects safety, tolerability, immunogenicity, pharmacokinetic and pharmacodynamic data. Early signs of anti-tumor activity will be recorded alongside adverse events to define acceptable doses and combination regimens. The trial is conducted at participating centers including Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.
Why it matters
Potential benefit: If successful, this approach could offer a new treatment option that controls tumors driven by KRAS mutations and potentially slows disease progression.
How similar studies have gone: Some KRAS-targeted agents (for example KRAS G12C inhibitors) and certain immunotherapy combinations have shown activity in selected KRAS-mutant cancers, but many KRAS alterations remain difficult to target and this specific approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. ≥18 years of age at time of informed consent. 2. Have a genetically tested report confirmed by the investigator or complete genetic testing during the screening period, with evidence of harboring any of required KRAS mutations 3. Histopathologically and/or cytologically confirmed locally advanced or metastatic solid tumors. 4. According to RECIST v1.1, at least one measurable lesion is required. 5. No severe hematological, hepatic, renal or coagulation dysfunction; laboratory test results during the screening period must meet the respective criteria specified in the study protocol. 6. Females of childbearing potential and males who are involved in heterosexual activity must agree to practice highly effective contraception. Exclusion Criteria: 1. Any other prior malignancy active within the previous 5 years, except for skin basal cell cancer that have been cured, superficial bladder cancer, or carcinoma in situ of the breast or cervix. 2. Has known symptomatic central nervous system (CNS) metastases, or CNS metastases requiring local CNS-directed therapy . 3. Received KRAS cancer vaccine before. 4. History of severe (≥ Grade 3) hypersensitivity reactions to immunotherapy. 5. History of allogeneic organ transplantation or graft-versus-host disease (GVHD). 6. Any active infection (except for hepatitis virus infection) requires systemic treatment. 7. Absence of spleen 8. Known psychiatric disorder or drug abuse that may interfere with the trial requirements 9. Participant is pregnant or breastfeeding or expecting to conceive within the projected duration of the study. 10. Other conditions that Investigators consider inappropriate for enrollment.
Where it's running
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China Recruiting
Study contacts
- Study coordinator: Xiao Zhang
- Email: xiao.zhang@abogenbio.com
- Phone: 8619931100148
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing SR-8541A for advanced solid tumors
This study is testing a new drug called SR-8541A to see if it can help people with advanced solid tumors that haven't responded to other treatments.
-
Lyophilized herpes zoster mRNA vaccine given to adults 40 and older
This trial tests two injections of ABO1108 versus placebo to see if the vaccine protects adults aged 40+ from shingles and how safe and workable it is.
-
Evaluating ABO2011 for advanced solid tumors
This study is testing a new treatment called ABO2011, alone or with another drug, to see if it can help people with advanced solid tumors feel better and improve their health.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.